Boehringer Ingelheim ’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study

Boehringer Ingelheim ’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study

Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news